Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03258008 2022-12-16

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

Phase 2 Terminated

3 enrolled 7 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT03364348 2022-10-19

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Phase 1 Completed

18 enrolled 17 charts

Breast

Breast Neoplasms

NCT02315066 2022-04-21

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Phase 1 Completed

174 enrolled 68 charts

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

NCT02951156 2020-12-17

Javelin DLBCL

Phase 3 Terminated

29 enrolled 24 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01307267 2020-03-17

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Phase 1 Completed

190 enrolled 65 charts

DermatologicGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Lymphoma, Large B-Cell, Diffuse

NCT02444793 2019-02-27

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Phase 1 Terminated

24 enrolled 34 charts

Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT02179918 2019-02-08

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

Phase 1 Completed

23 enrolled 27 charts

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

InCITe

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Rituximab + Immunotherapy in Follicular Lymphoma

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

JAVELIN Medley

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Javelin DLBCL

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)